The estimated Net Worth of Gregory K. Chow is at least $1.9 Million dollars as of 10 July 2020. Mr. Chow owns over 126,668 units of Aptose Biosciences Inc stock worth over $85,920 and over the last 6 years he sold APTO stock worth over $766,341. In addition, he makes $1,048,980 as Chief Financial Officer and Executive Vice President at Aptose Biosciences Inc.
Gregory has made over 3 trades of the Aptose Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 126,668 units of APTO stock worth $766,341 on 10 July 2020.
The largest trade he's ever made was selling 126,668 units of Aptose Biosciences Inc stock on 10 July 2020 worth over $766,341. On average, Gregory trades about 21,310 units every 69 days since 2019. As of 10 July 2020 he still owns at least 232,846 units of Aptose Biosciences Inc stock.
You can see the complete history of Mr. Chow stock trades at the bottom of the page.
Gregory Kwok Lee Chow CPA serves as Chief Financial Officer, Executive Vice President of the Company. Previously, Mr. Chow served as Managing Director, Director of Private Placements at Wedbush Securities from 2012 to 2013, where he led the private placement capital activities within the Life Sciences Investment Banking Group. Prior to joining Wedbush, he was a Director in the Private Placements / Equity Capital Markets Group at RBC Capital Markets from 2006 to 2011, where he led life science private capital activities. From 2003 to 2006, he led the Private Capital Group at Wells Fargo Securities and was a Senior Auditor at BDO Seidman, LLP in their Century City, CA office. Mr. Chow is a Certified Public Accountant (inactive) in the State of California. Mr. Chow received his MBA in Finance from The Wharton School at the University of Pennsylvania, and his BA in Business Economics with an emphasis in Accounting from the University of California, Santa Barbara.
As the Chief Financial Officer and Executive Vice President of Aptose Biosciences Inc, the total compensation of Gregory Chow at Aptose Biosciences Inc is $1,048,980. There are 1 executives at Aptose Biosciences Inc getting paid more, with William Rice having the highest compensation of $1,511,900.
Gregory Chow is 47, he's been the Chief Financial Officer and Executive Vice President of Aptose Biosciences Inc since 2019. There are 10 older and 2 younger executives at Aptose Biosciences Inc. The oldest executive at Aptose Biosciences Inc is Denis Burger, 75, who is the Lead Independent Director.
Gregory's mailing address filed with the SEC is C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO, A6, M2J 4R3.
Over the last 6 years, insiders at Aptose Biosciences Inc have traded over $2,827,381 worth of Aptose Biosciences Inc stock and bought 538,629 units worth $767,189 . The most active insiders traders include Erich Platzer, Bernd R. Seizinger, and William G. Rice. On average, Aptose Biosciences Inc executives and independent directors trade stock every 59 days with the average trade being worth of $14,277. The most recent stock trade was executed by Bernd R. Seizinger on 22 September 2023, trading 17,000 units of APTO stock currently worth $53,380.
aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
Aptose Biosciences Inc executives and other stock owners filed with the SEC include: